Experimental oral drug for advanced solid tumors
Part of Cancer clinical trials.
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced solid cancer (like liver, colorectal, stomach, or endometrial) that has grown despite treatment or you can't have standard treatment.
- You have a tumor that can be seen on a scan.
- You are generally well enough to care for yourself (ECOG score 0 or 1) and expected to live at least 12 weeks.
- You must have had a recent tumor gene test (or be willing to give a tumor sample for testing), especially for FGFR gene changes.
- You can swallow and absorb oral medication, and your heart, liver, and kidney function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug (CS231295) for people with advanced solid tumors who have run out of standard options. It aims to see how safe the drug is and how well it controls the cancer, and may slow tumor growth. You must be in reasonably good health with adequate organ function.
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.